Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 3, 2024, reports on clinical trial updates for Jemperli (dostarlimab) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The filing focuses on a Phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating dostarlimab as a first-line treatment for locally advanced mismatch repair deficient (dMMR) rectal cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or quarterly results.
Material Changes and Clinical Results
- Clinical Complete Response (cCR): Updated analysis expanded to 42 patients, showing a 100% clinical complete response rate (no evidence of disease) after treatment with dostarlimab.
- Durability: In the first 24 patients evaluated, a sustained clinical complete response was observed with a median follow-up of 26.3 months (95% CI: 12.4-50.5).
- Safety Profile: No adverse events of grade 3 or higher were reported in this trial; the safety profile was consistent with known data for the agent.
- Comparison to Standard of Care: Current standard of care involves chemotherapy, radiation, and surgery, which can lead to long-term adverse effects (bowel, urinary, sexual dysfunction) and distant metastasis in nearly one-third of patients.
Guidance, Outlook, and Risks
Outlook and Pipeline: GSK is advancing registrational studies to confirm these findings. The AZUR-1 trial (Phase II) is investigating dostarlimab as monotherapy to replace chemotherapy, radiation, and/or surgery for treatment-naïve patients with dMMR/MSI-H locally advanced rectal cancer. The AZUR-2 trial (Phase III) is evaluating perioperative dostarlimab versus standard of care in untreated T4N0 or Stage III dMMR/MSI-H colon cancer.
Regulatory Status: Dostarlimab is not currently approved anywhere in the world for the frontline treatment of locally advanced dMMR rectal cancer. It is approved in the US and EU for dMMR/MSI-H endometrial cancer and recurrent/advanced solid tumors under accelerated approval.
Risks and Contingencies: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties, including those described in GSK's 2023 Form 20-F and Q1 2024 results. Continued approval for the solid tumor indication may be contingent upon verification of clinical benefit in confirmatory trials.
Investor Verification Checklist
- Verify the enrollment status and primary endpoints of the AZUR-1 and AZUR-2 registrational trials.
- Confirm the timeline for potential regulatory submissions based on the AZUR-1 Phase II results.
- Review the full safety data and long-term follow-up for the 42 patients in the MSK study.
- Assess the competitive landscape for immuno-oncology treatments in rectal cancer.
- Check for any updates on the commercial performance of Jemperli in its currently approved indications (endometrial cancer).